New Medical Strategies for Midgut Carcinoids

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

New Medical Strategies for Midgut Carcinoids



Anti-Cancer Agents in Medicinal Chemistry, 10(3): 250-269.

Author(s): Ola Nilsson, Yvonne Arvidsson, Viktor Johanson, Eva Forssell-Aronsson and Hakan Ahlman.

Affiliation: Department of Surgery, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden.

Abstract

Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.

Keywords:

monoclonal antibody, growth factor receptor, Angiogenesis inhibition, multikinase inhibition, neuroendocrine tumour, radionuclide therapy, small molecule inhibitor, somatostatin receptor.



Download Free Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 10
Issue Number: 3
First Page: 250
Last Page: 269
Page Count: 20
DOI: 10.2174/1871520611009030250
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science